Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Blum

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Hematological Oncology|March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioningMehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Leukemia|February 10, 2019
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyKrzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Hematological Oncology|March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioningMehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Leukemia|February 10, 2019
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyKrzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Pageof 12